Gd-EOB-DTPA MRI and serum biomarkers differentiate scirrhous HCC from mass-forming cholangiocarcinoma in HBV patients

Gd-EOB-DTPA MRI model (non-thin rim enhancement, enhancing capsule, opposed-phase signal loss) plus serum biomarkers differentiated scirrhous HCC from mass-forming cholangiocarcinoma in HBV patients with AUC 0.951 (sensitivity 85.9%, specificity 88.4%), externally validated AUC…

• Training AUC 0.951 (sensitivity 85.9%, specificity 88.4%); external validation AUC 0.939 (sensitivity 85.0%, specificity 88.9%).
• SHCC showed significantly lower necrosis incidence than IMCC (p=0.03 training, p=0.002 validation).

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.